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ABSTRACT
Purpose: Previous phases of trachoma mapping in Pakistan completed baseline surveys in 38
districts. To help guide national trachoma elimination planning, we set out to estimate trachoma
prevalence in 43 suspected-endemic evaluation units (EUs) of 15 further districts.
Methods: We planned a population-based trachoma prevalence survey in each EU. Two-stage
cluster sampling was employed, using the systems and approaches of the Global Trachoma
Mapping Project. In each EU, residents aged ≥1 year living in 30 households in each of 26 villages
were invited to be examined by trained, certified trachoma graders. Questionnaires and direct
observation were used to evaluate household-level access to water and sanitation.
Results: One EU was not completed due to insecurity. Of the remaining 42, three EUs had
trichiasis prevalence estimates in ≥15-year-olds ≥0.2%, and six (different) EUs had prevalence
estimates of trachomatous inflammation—follicular (TF) in 1–9-year-olds ≥5%; each EU requires
trichiasis and TF prevalence estimates below these thresholds to achieve elimination of trachoma
as a public health problem. All six EUs with TF prevalences ≥5% were in Khyber Pakhtunkhwa
Province. Household-level access to improved sanitation ranged by EU from 6% to 100%.
Household-level access to an improved source of water for face and hand washing ranged by
EU from 37% to 100%.
Conclusion: Trachoma was a public health problem in 21% (9/42) of the EUs. Because the current
outbreak of extremely drug-resistant typhoid in Pakistan limits domestic use of azithromycin mass
drug administration, other interventions against active trachoma should be considered here.
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Introduction
Trachoma is a neglected tropical disease1 and the leading
infectious cause of blindness worldwide.2 Trachomatous
inflammation— follicular (TF) and/or trachomatous
inflammation—intense (TI) are signs of active trachoma
that can occur when certain strains3,4 of the bacterium
Chlamydia trachomatis infect the conjunctivae. Trichiasis
is a complication of trachoma that occurs after multiple
episodes of infection and associated inflammation,5
typically in adulthood.6–8 It is characterized by in-turned
eyelashes touching the eyeball, which may lead to pain,
corneal ulceration, corneal scarring, and visual
impairment.9–11
To eliminate trachoma as a public health problem,12 the
World Health Organization (WHO) recommends imple-
mentation of the SAFE strategy: Surgery to redirect in-
turned eyelashes away from the eye; Antibiotics to clear
infection; and Facial cleanliness and Environmental
improvement to reduce transmission.13,14 In order to
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plan and implement SAFE interventions, population-based
prevalence surveys of TF and trichiasis are needed in dis-
tricts suspected to be trachoma-endemic.15,16 Public
health-level implementation of S is indicated in districts
where trachomatous trichiasis prevalence is ≥0.2% in per-
sons aged ≥15 years, while public health-level implementa-
tion of A, F and E is indicated in districts where TF
prevalence is ≥5% in children aged 1–9 years.17
In Pakistan in the 1950s, trachoma was believed to
account for >60% of all blindness nationally.18 The
country now has a population of over 200 million peo-
ple, 63% of whom live in rural areas.19 In addition to its
Federal Capital Territory (Islamabad), Pakistan is com-
prised of four provinces (Baluchistan, Khyber
Pakhtunkhwa, Punjab and Sindh), two autonomous
territories (Azad Jammu & Kashmir, and Gilgit-
Baltistan) and the Federally Administered Tribal Area.
These province-level units are further split into the
successively lower administrative tiers of 34 divisions,
149 districts (zillahs), and 588 sub-districts (tehsils).
From 2002 to 2004, the National Trachoma Task Force
of Pakistan oversaw Trachoma Rapid Assessments
(TRAs)20 covering 233 villages in Baluchistan (49 TRAs),
North-West Frontier Province [renamed Khyber
Pakhtunkhwa in 2010] (69), Punjab (67), Sindh (23) and
Northern Areas [renamed Gilgit-Baltistan in 2009] (25).21
Based on these TRAs, from 2011 to 2013, prevalence sur-
veys were undertaken over three phases in 38 districts. In
each of those districts, 70 villages were chosen with
a probability-proportional-to-size sampling strategy. In
every selected village, systematic sampling was used to
select households to facilitate examination of 100 adults.
In every second selected village, 100 children were also
examined. This produced relatively large sample sizes of
7000 adults and 3500 children per district.22 In Punjab
province, the districts of DG Khan (0.77%), Hafizabad
(0.39%),Narowal (1.01%) andVehari (0.36%)had trichiasis
prevalences in adults ≥0.2%; elsewhere, only Chitral
(Khyber Pakhtunkhwa, 1.3%), Pishin (Baluchistan, 0.47%)
and Skardu (Gilgit Baltistan, 0.93%) exceeded this
threshold.
Across all provinces, only the districts of Chitral
(Khyber Pakhtunkhwa, 12.7%) and Shadadkot (Sindh,
9.9%), had active trachoma (TF and/or TI) prevalence
in 1–9-year-olds of ≥5%. Access to clean water was
noted to be a major problem in almost all
districts.22The aim of the present work was to (1)
estimate the prevalence of TF among children aged
1–9 years and of trichiasis among persons aged ≥15
years, and (2) determine the proportion of households
with access to improved water and sanitation facilities,
in selected areas of Pakistan. This formed part of the
Global Trachoma Mapping Project (GTMP).23 This
information was needed to direct trachoma elimination
efforts at national, provincial and sub-district levels.
Methods
Prior to this series of surveys, as mentioned above, tra-
choma surveys had been completed in 38 districts of
Pakistan. The work described here was considered
a fourth phase of surveys. It was completed in 2015 and
was intended by the National Trachoma Task Force to
complete baseline surveys in suspected-endemic areas
which did not then have valid prevalence data. Such sus-
pected-endemic-but-unmapped areas were found across 29
districts, incorporating an estimated total population of
40,720,310. Due to time limitations and insecurity in
some areas, 14 of the 29 districts were excluded from the
plan. In the remaining 15 districts, we deprioritized urban
areas (where risk of trachoma is considerably lower24), and
constructed rural evaluation units (EUs) of approximately
200,000–300,000 people, as a compromise between the
WHO-recommended25 100,000–250,000-person EU size,
and the relatively low perceived likelihood of identifying
populations here in which trachoma was a public health
problem. (A similar compromise has been reached
elsewhere.26,27) This produced a total of 43 EUs (Table 1).
In each of these, a separate EU-level survey was planned
and commenced. (In one EU, however, insecurity pre-
vented completion.)
Following standard GTMP approaches,28,29 a two-
stage cluster sampling method was used to determine
which villages and households would be included in
each survey. In each EU, 26 villages were randomly
selected. Within each of those villages, a compact seg-
ment of 30 households was randomly selected and
Table 1. Districts in which baseline trachoma prevalence sur-
veys were commenced, Global Trachoma Mapping Project,
Pakistan, October–December 2015.
Province # District Population
Number of evaluation
units
Baluchistan 1 Nasirabad 314,744 1
2 Nushki 176,000 1
Khyber
Pakhtunkhwa
3 Karak 551,419 2
4 Mansehra 1,475,634 5
5 Mardan 1,868,928 4
Punjab 6 Gujranwala 4,353,203 6
7 Layyah 1,434,817 4
8 Lodhran 1,499,904 4
9 Sahiwal 2,359,288 5
Sindh 9 Ghotki 1,242,303 3
10 Jamshoro 726,642 2a
Azad Jammu &
Kashmir
12 Bagh 341,254 1
13 Kotli 954,880 3
Gilgit-Baltistan 14 Ghizer 153,879 1
15 Ghanche 113,108 1
Total 17,566,004 43
aCompletion of mapping was not possible in one of the two evaluation
units of Jamshoro.
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residents of those 30 households aged ≥1 year were
enumerated and invited to participate.
Field team structure and training
In Baluchistan and Khyber Pakhtunkhwa, each survey
team was composed of one female grader, one male
grader, one female recorder and one male recorder. In
these provinces, for cultural reasons, female and male
team members were unable to access male and female
sections of the household, respectively, or examine
household residents of the opposite gender. Each team
had a driver and was accompanied by a local village
guide. In Sindh, Punjab, Azad Jammu & Kashmir, and
Gilgit-Baltistan, each survey team was composed of one
grader and one recorder, with one driver for every 1–2
teams, depending on the geography of deployment; as
in Baluchistan and Khyber Pakhtunkhwa, each team
was accompanied by a local village guide.
Ophthalmologists supervised the teams.
Extensive searches around Faisalabad for trachoma-
endemic localities in which to undertake field-based
grader training and testing resulted in very few cases
of active trachoma being identified, and it was resolved
instead to undertake this process in Sokoto, Nigeria,
where a number of local government areas still had TF
prevalences of 5.0–9.9%.30 In August 2015, a total of 23
grader trainees went to Sokoto; 16 passed the inter-
grader agreement tests and were certified to participate
in the surveys.28 Three recorder trainers were also
trained in Sokoto; they later conducted workshops in
Pakistan to train 26 recorders. Version 2 of the GTMP
training package31 was used. This included the use of
questions about previous trichiasis management being
asked of survey subjects found to have trichiasis,32 but
not recording of the presence or absence of trachoma-
tous conjunctival scarring (TS)9 in eyes diagnosed with
trichiasis.33 The latter element (recording of the pre-
sence or absence of TS) was introduced half-way
through the surveys, in the form of Version 3 of the
GTMP system; this was introduced to field team mem-
bers via a specific training session.34 TS data are there-
fore only available for the last 19 EUs mapped.
Fieldwork
Field teams liaised with district health authorities to find
selected villages. Teams then created maps to plan survey
routes. Schedules were communicated to the programme
officer and supervisors on a weekly basis, to facilitate
support.
Once in the field, given potential security concerns,
particular emphasis was given to gaining district-,
community-, household- and individual-level consent for
the survey. The ophthalmologist led community-level
engagement. The voluntary nature of participation by com-
munity residentswas emphasized to communities through-
out the survey process. Explicit consent from heads of
households was required before field teams entered any
household. Official government mission documents, iden-
tity cards, up-to-date points of contact and escalation chan-
nels were carried by field teams at all times.
All adults and children aged ≥1 year and residents in
selected households were registered and asked to con-
sent to eye examination. Grading was undertaken
under 2.5× magnification, and the presence or absence
of trichiasis, TF and TI recorded, using standard WHO
simplified trachoma grading system definitions.9 When
an eye was diagnosed as having trichiasis, the subject
was asked whether a health worker had previously
recommended surgery or epilation; for (only) the last
19 EUs, in addition, the presence or absence of TS in
that eye was recorded.
Data were collected electronically using LINKS/GTMP
software based on Open Data Kit, running on the
Android operating system.28,35 Teams moved from one
household to the next. Data collected in the field were
encrypted and securely transferred to a central data host-
ing, management, approval, and reporting system, where
they were rapidly analysed, as previously described.28
Graders used disposable latex gloves or cleaned their
hands with 70% alcohol after each examination to avoid
spreading infection. Basic treatment, such as 1% tetracy-
cline eye ointment or analgesics, were provided on the
spot to those in need. Patients requiring referral to hospi-
tal, including those with trichiasis, were promptly referred.
Analysis
Standard GTMP approaches28,29 were used for data
cleaning, analysis, health ministry review, and approval.
In the first 23 completed EUs, lacking information on
the presence or absence of TS in eyes with trichiasis, we
calculated the prevalence of “any trichiasis”; for the last
19 completed EUs, we calculated the prevalence of both
any trichiasis and “trichiasis+TS”, defined here as the
presence of both trichiasis and TS (or the inability of
the examiner to evert the lid to look for TS, presumed
to be due to dense scarring) in the same eye.
Ethical considerations
Ethical approval was given by the National Committee
of Eye Health (1349/15) and the ethics committee of
the London School of Hygiene & Tropical Medicine
(6319 and 8355). For many districts, non-objection
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certificates were also obtained from the relevant
District Health Authority. Because of low levels of
literacy in the target population, field teams obtained
consent from prospective participants verbally. Consent
for individuals aged <15 years was given by a parent or
guardian. Individuals with trachoma or other medical
problems that were diagnosed by the field team were
treated or referred (using a formal, specifically designed
referral slip), as appropriate.
Results
Fieldwork was undertaken from October to
December 2015. Insecurity prevented completion of
mapping in one EU; the incomplete data have been
excluded from this presentation. The mean number of
children examined per household varied considerably
from one EU to another. In some EUs, recruitment of
children in the initially-selected 26 villages yielded low
numbers of 1–9-year-olds examined: in one case, this
number was 558. Extra villages were selected (at ran-
dom, using the original list of villages in the EU) in
these EUs to compensate for the unexpectedly small
household size. In some EUs, when mean household-
level GPS co-ordinates were plotted by village, there
was a clear overlap between the previously planned
sub-Tehsil-level EUs. Borders for each EU occasionally
needed to be adjusted for survey purposes (with the
creation of new shapefiles), resulting in uneven num-
bers of villages sampled (Table 2).
In all, a total of 33,432 households were visited in 1119
clusters across 42 EUs. Those households were home to
56,345 1–9-year-olds and 96,268 ≥ 15-year-olds.
Of the 56,345 enumerated 1–9-year-olds, 54,334 (96%)
consented and were examined, 1669 (3%) were absent on
the day of the visit, 338 (1%) refused consent and 4 were
not examined for other reasons. A mean of 1294 1–9-year-
olds was examined per EU (range 768–2243). As shown in
Table 2, the age-adjusted EU-level TF prevalence in
1–9-year-olds ranged from 0% in the EU covering
Dhirkot, Bagh and Hari Ghal, to 13.6% (95%CI 9.3–18.3)
in FR Kala Dhaka. Six (14%) of 42 EUs had age-adjusted
TF prevalence estimates of ≥5% (Figure 1, Table 2).
Of 96,268 enumerated ≥15-year-olds, 85,832 (89%)
were examined, 8775 (9%) were absent on the day of the
visit, 1648 (2%) did not agree to participate and 13 were
not examined for other reasons (Table 2). The age- and
gender-adjusted trichiasis prevalence in ≥15-year-olds
(regardless of the presence or absence of TS) ranged
from 0% to 2.96%. Twenty-two (52%) of 42 EUs had
age- and gender-adjusted trichiasis prevalence estimates
of 0%, 16 (38%) had non-zero trichiasis prevalence esti-
mates that were less than the elimination threshold of
0.2%,17 and four (10%) had trichiasis prevalence estimates
of ≥0.2% in adults (Figure 2, Table 2). In only one EU
(Ghotki Taluka, Khangarh Taluka) was the adjusted pre-
valence of trichiasis+TS substantially different from the
adjusted prevalence of trichiasis (Table 2).
Household-level access to an improved source of
water for face and hand washing ranged from 37% in
the EU covering Chattar Sub-Tehsil and Dera Murad
Jamali Tehsil, to 100% in 22 (52%) of the 42 EUs
surveyed. In 36 (86% of) EUs, ≥80% of households
had access to an improved source of water for face
and hand washing (Table 3).
The proportion of households with access to an
(improved or unimproved) source of water for face
and hand washing within 1 km of the house ranged
from 57% in the EU covering Sehwan Taluka to 100%
in 19 (45%) of the 42 EUs surveyed. In 40 (95%) of the
42 EUs surveyed, ≥80% of households had access to
a source of water for face and hand washing within
1 km of the house (Table 3).
Household-level access to improved sanitation ranged
from a low of 6% in Genchi to a high of 100% in 4 (10%)
of 42 EUs. In 23 (55%) of the EUs, ≥80% of households
had access to improved sanitation (Table 3).
Discussion
Data from this fourth phase of baseline mapping repre-
sent another important step towards complete categor-
ization of the distribution and burden of trachoma in
Pakistan. Only three of 42 EUs mapped were shown to
qualify for public-health-level deployment of trichiasis
surgical services, and only six EUs (all in Khyber
Pakhtunkhwa) were shown to qualify for intervention
with A, F, and E components of SAFE.36 There was no
overlap between the group of three EUs qualifying for
S and the group of six EUs qualifying for A, F, and
E. The very high prevalence of trichiasis in Wazirabad
Tehsil 1 (2.96%, 95%CI 0.71–5.76) was unexpected and
therefore requires confirmation, likely through a repeat
survey. Low prevalences of active trachoma in the 19
EUs we surveyed in Punjab match the low prevalence
of active disease recorded in children of Dera Ghazi
Khan district, Punjab, by other investigators, in 2014.37
Experience elsewhere suggests that SAFE strategy
implementation would have a good chance of success-
fully eliminating trachoma here.38–40 Unfortunately, the
recent outbreak of extensively drug-resistant typhoid in
Pakistan41,42 may prevent the national trachoma pro-
gramme from using azithromycin mass drug administra-
tion, the SAFE strategy intervention with the strongest
evidence for effect.43 For EUs with TF prevalence esti-
mates ≥5%, use of topical tetracycline eye ointment
158 A. A. KHAN ET AL.
Ta
bl
e
2.
N
um
be
r
of
1–
9-
ye
ar
-o
ld
s
an
d
nu
m
be
r
of
≥
15
-y
ea
r-
ol
ds
re
si
de
nt
,e
xa
m
in
ed
,a
bs
en
t
an
d
re
fu
se
d;
pr
ev
al
en
ce
of
tr
ac
ho
m
at
ou
s
in
fla
m
m
at
io
n—
fo
lli
cu
la
r
(T
F)
,a
nd
pr
ev
al
en
ce
of
tr
ic
hi
as
is
(a
nd
,w
he
re
po
ss
ib
le
,t
ric
hi
as
is
+
TS
,s
ee
te
xt
)
un
kn
ow
n
to
th
e
he
al
th
sy
st
em
,b
y
ev
al
ua
tio
n
un
it,
G
lo
ba
lT
ra
ch
om
a
M
ap
pi
ng
Pr
oj
ec
t,
Pa
ki
st
an
,O
ct
ob
er
–D
ec
em
be
r
20
15
.
1–
9-
ye
ar
-o
ld
s
≥
15
-y
ea
r-
ol
ds
D
is
tr
ic
t
Ev
al
ua
tio
n
un
it
N
um
be
r
of
vi
lla
ge
s
sa
m
pl
ed
Re
si
de
nt
Ex
am
in
ed
Ab
se
nt
Re
fu
se
d
O
th
er
TF
pr
ev
al
en
ce
a ,
%
(9
5%
CI
)
Re
si
de
nt
Ex
am
in
ed
Ab
se
nt
Re
fu
se
d
O
th
er
Tr
ic
hi
as
is
pr
ev
al
en
ce
b
,%
(9
5%
CI
)
Tr
ic
hi
as
is
+
TS
pr
ev
al
en
ce
b
,%
(9
5%
CI
)
N
as
ira
ba
d
Ch
at
ta
r
Su
b-
Te
hs
il,
D
er
a
M
ur
ad
Ja
m
al
iT
eh
si
l
26
22
28
22
27
1
0
0
1.
3
(0
.6
–2
.2
)
19
60
18
89
62
9
0
0.
01
(0
.0
–0
.0
2)
0.
01
(0
.0
–0
.0
2)
N
us
hk
i
N
us
hk
iT
eh
si
l
26
21
19
21
03
10
6
0
0.
2
(0
.0
–0
.4
)
23
25
22
07
69
49
0
0.
0
(0
.0
–0
.0
)
0.
0
(0
.0
–0
.0
)
Ka
ra
k
Ba
nd
a
D
au
d
Sh
ah
Te
hs
il,
Ka
ra
k
Te
hs
il
37
20
96
18
94
19
9
2
1
9.
1
(6
.6
–1
1.
6)
39
81
30
02
81
4
15
9
6
0.
13
(0
.0
–0
.2
4)
N
D
Ka
ra
k
Ta
kh
at
N
as
ra
ti
Te
hs
il
21
14
31
12
45
18
4
1
1
9.
4
(5
.6
–1
3.
0)
20
38
15
38
43
9
61
0
0.
0
(0
.0
–0
.0
)
N
D
M
an
se
hr
a
Ba
la
Ko
t
Te
hs
il
26
14
25
12
72
15
2
1
0
1.
0
(0
.3
–1
.6
)
20
37
15
98
37
2
67
0
0.
0
(0
.0
–0
.0
)
N
D
M
an
se
hr
a
FR
Ka
la
D
ha
ka
26
14
90
14
37
52
1
0
13
.6
(9
.3
–1
8.
3)
18
92
15
26
34
1
25
0
0.
0
(0
.0
–0
.0
)
N
D
M
an
se
hr
a
M
an
se
hr
a
Te
hs
il
1
27
14
39
12
81
15
1
7
0
2.
0
(1
.0
–3
.3
)
21
59
15
85
43
9
13
5
0
0.
0
(0
.0
–0
.0
)
N
D
M
an
se
hr
a
M
an
se
hr
a
Te
hs
il
2
26
11
90
10
67
12
3
0
0
4.
1
(2
.0
–6
.6
)
21
41
16
74
44
2
25
0
0.
0
(0
.0
–0
.0
)
N
D
M
an
se
hr
a
O
gh
iT
eh
si
l
26
12
21
11
60
61
0
0
6.
0
(4
.0
–7
.6
)
21
42
16
57
41
8
67
0
0.
0
(0
.0
–0
.0
)
N
D
M
ar
da
n
M
ar
da
n
Te
hs
il
1
27
15
69
15
30
39
0
0
5.
7
(4
.0
–7
.4
)
20
57
16
06
41
9
32
0
0.
0
(0
.0
–0
.0
)
N
D
M
ar
da
n
M
ar
da
n
Te
hs
il
2
35
19
74
19
28
46
0
0
5.
6
(4
.0
–7
.2
)
27
45
21
88
51
4
43
0
0.
0
(0
.0
–0
.0
)
N
D
M
ar
da
n
M
ar
da
n
Te
hs
il
3
16
87
7
85
1
26
0
0
3.
9
(2
.0
–5
.6
)
12
53
10
18
22
2
13
0
0.
0
(0
.0
–0
.0
)
N
D
M
ar
da
n
Ta
kh
t
Bh
ai
Te
hs
il
27
15
33
15
06
26
1
0
3.
7
(2
.3
–5
.1
)
21
55
17
24
39
6
35
0
0.
0
(0
.0
–0
.0
)
N
D
G
uj
ra
nw
al
a
G
uj
ra
nw
al
a
Te
hs
il
1
30
96
0
95
2
0
7
1
1.
0
(0
.1
–2
.2
)
24
91
23
96
11
82
2
0.
02
(0
.0
–0
.0
7)
N
D
G
uj
ra
nw
al
a
G
uj
ra
nw
al
a
Te
hs
il
2
22
78
4
78
4
0
0
0
0.
2
(0
.0
–0
.5
)
20
47
20
42
0
5
0
0.
06
(0
.0
–0
.1
5)
N
D
G
uj
ra
nw
al
a
Ka
m
ok
e
Te
hs
il
26
11
84
10
23
19
14
2
0
0.
3
(0
.0
–0
.6
)
22
10
19
32
16
1
11
7
0
0.
03
(0
.0
–0
.0
9)
N
D
G
uj
ra
nw
al
a
N
ow
sh
er
a
Te
hs
il
26
17
18
17
13
1
4
0
0.
9
(0
.0
–1
.6
)
19
38
19
20
11
4
3
0.
03
(0
.0
–0
.0
8)
N
D
G
uj
ra
nw
al
a
W
az
ira
ba
d
Te
hs
il
1
29
92
9
87
8
39
12
0
0.
9
(0
.1
–2
.3
)
24
04
21
73
17
1
60
0
2.
96
(0
.7
1–
5.
76
)
N
D
G
uj
ra
nw
al
a
W
az
ira
ba
d
Te
hs
il
2
23
96
4
95
2
12
0
0
1.
6
(0
.6
–3
.0
)
20
02
18
86
96
20
0
0.
07
(0
.0
–0
.2
0)
0.
0
(0
.0
–0
.0
)
La
yy
ah
Ch
ou
ba
ra
Te
hs
il
38
12
27
12
20
6
1
0
3.
4
(2
.0
–4
.7
)
28
96
27
09
57
13
0
0
0.
0
(0
.0
–0
.0
)
N
D
La
yy
ah
Ka
ro
r
Te
hs
il
26
89
9
89
6
2
1
0
0.
9
(0
.2
–2
.0
)
17
61
15
93
6
16
2
0
0.
08
(0
.0
–0
.2
5)
0.
08
(0
.0
–0
.2
5)
La
yy
ah
Le
ia
h
Te
hs
il
1
26
10
92
10
83
7
2
0
0.
8
(0
.0
–2
.0
)
23
13
22
76
30
7
0
0.
0
(0
.0
–0
.0
)
0.
0
(0
.0
–0
.0
)
La
yy
ah
Le
ia
h
Te
hs
il
2
26
11
29
11
21
5
3
0
0.
2
(0
.0
–0
.6
)
21
43
21
07
34
2
0
0.
01
(0
.0
–0
.0
4)
0.
0
(0
.0
–0
.0
)
Lo
dh
ra
n
D
un
ya
pu
r
Te
hs
il
26
13
15
12
56
3
56
0
1.
8
(1
.1
–2
.6
)
22
74
19
63
20
6
10
5
0
0.
0
(0
.0
–0
.0
)
N
D
Lo
dh
ra
n
Ka
hr
or
Te
hs
il
25
14
05
12
86
11
9
0
0
2.
5
(1
.0
–3
.7
)
24
79
22
74
19
3
12
0
0.
0
(0
.0
–0
.0
)
N
D
Lo
dh
ra
n
Lo
dh
ra
n
Te
hs
il
1
25
17
43
17
43
0
0
0
1.
2
(0
.4
–2
.3
)
23
91
23
69
20
2
0
0.
02
(0
.0
–0
.0
6)
0.
0
(0
.0
–0
.0
)
Lo
dh
ra
n
Lo
dh
ra
n
Te
hs
il
2
27
22
44
22
43
1
0
0
1.
8
(0
.9
–3
.1
)
21
62
21
32
27
3
0
0.
08
(0
.0
–0
.1
6)
0.
08
(0
.0
–0
.1
6)
Sa
hi
w
al
Ch
ic
ha
w
at
ni
Te
hs
il
1
26
11
96
11
17
44
34
1
0.
6
(0
.2
–1
.2
)
23
42
19
92
25
7
93
0
0.
02
(0
.0
–0
.0
7)
0.
0
(0
.0
–0
.0
)
Sa
hi
w
al
Ch
ic
ha
w
at
ni
Te
hs
il
2
26
82
9
76
8
56
5
0
0.
9
(0
.0
–2
.4
)
27
98
22
35
55
4
9
0
0.
02
(0
.0
–0
.6
)
0.
02
(0
.0
–0
.0
6)
Sa
hi
w
al
Sa
hi
w
al
Te
hs
il
1
27
10
88
98
8
90
10
0
2.
3
(1
.2
–4
.0
)
23
24
22
79
42
3
0
0.
0
(0
.0
–0
.0
)
0.
0
(0
.0
–0
.0
)
Sa
hi
w
al
Sa
hi
w
al
Te
hs
il
2
26
93
5
90
6
29
0
0
1.
4
(0
.7
–2
.3
)
25
88
25
10
50
28
0
0.
0
(0
.0
–0
.0
)
0.
0
(0
.0
–0
.0
)
Sa
hi
w
al
Sa
hi
w
al
Te
hs
il
3
33
11
75
11
57
6
12
0
0.
3
(0
.0
–0
.8
)
25
70
24
49
10
2
17
2
0.
0
(0
.0
–0
.0
)
N
D
G
ho
tk
i
D
ah
rk
iT
al
uk
a
26
12
68
12
61
7
0
0
0.
7
(0
.0
–1
.8
)
18
65
18
39
26
0
0
0.
0
(0
.0
–0
.0
)
0.
0
(0
.0
–0
.0
)
G
ho
tk
i
G
ho
tk
iT
al
uk
a,
Kh
an
ga
rh
Ta
lu
ka
27
10
13
10
10
3
0
0
0.
5
(0
.1
–0
.8
)
21
12
20
30
81
1
0
0.
36
(0
.1
4–
0.
67
)
0.
14
(0
.0
–0
.3
4)
G
ho
tk
i
M
irp
ur
M
at
he
lo
Ta
lu
ka
,
U
ba
ur
o
Ta
lu
ka
26
90
3
89
5
8
0
0
0.
8
(0
.3
–1
.4
)
21
06
20
24
81
1
0
0.
03
(0
.0
–0
.0
9)
0.
03
(0
.0
–0
.0
9)
Ja
m
sh
or
o
Se
hw
an
Ta
lu
ka
26
99
4
99
3
1
0
0
0.
1
(0
.0
–0
.4
)
17
67
17
57
10
0
0
0.
0
(0
.0
–0
.0
)
N
D
Ba
gh
D
hi
rk
ot
,B
ag
h,
H
ar
iG
ha
l
26
12
69
12
06
63
0
0
0.
0
(0
.0
–0
.0
)
27
49
25
08
23
4
7
0
0.
0
(0
.0
–0
.0
)
0.
0
(0
.0
–0
.0
)
Ko
tli
Ko
tli
Su
b–
Te
hs
il
1
26
17
70
17
30
32
8
0
0.
1
(0
.0
–0
.3
)
24
56
21
13
32
0
23
0
0.
0
(0
.0
–0
.0
)
N
D
Ko
tli
Ko
tli
Su
b–
Te
hs
il
2
27
19
15
18
68
33
14
0
0.
2
(0
.0
–0
.4
)
24
27
20
82
31
3
32
0
0.
14
(0
.0
6–
0.
25
)
0.
13
(0
.0
5–
0.
24
)
Ko
tli
Ko
tli
Su
b–
Te
hs
il
3
24
13
93
13
82
3
8
0
0.
1
(0
.0
–0
.3
)
20
67
19
80
86
1
0
0.
49
(0
.2
2–
0.
87
)
0.
45
(0
.1
9–
0.
82
)
G
hi
ze
r
G
hi
ze
r
26
11
98
11
93
5
0
0
0.
5
(0
.1
–1
.3
)
28
97
26
00
29
5
2
0
0.
14
(0
.0
6–
0.
25
)
0.
13
(0
.0
5–
0.
24
)
G
ha
nc
he
G
ha
nc
he
26
12
14
12
09
5
0
0
0.
6
(0
.0
–1
.6
)
28
04
24
50
35
4
0
0
0.
49
(0
.2
2–
0.
87
)
0.
45
(0
.1
9–
0.
82
)
a A
dj
us
te
d
fo
r
ag
e
in
1-
ye
ar
ag
e
ba
nd
s
(s
ee
te
xt
)
b
U
nk
no
w
n
to
th
e
he
al
th
sy
st
em
,a
dj
us
te
d
fo
r
ge
nd
er
an
d
ag
e
in
5-
ye
ar
ag
e
ba
nd
s
(s
ee
te
xt
).
CI
,c
on
fid
en
ce
in
te
rv
al
;N
D
,n
o
da
ta
OPHTHALMIC EPIDEMIOLOGY 159
Figure 1. Evaluation-unit-level prevalence of trachomatous inflammation—follicular (TF), adjusted for age (see text), Global
Trachoma Mapping Project, Pakistan, October–December 2015.
Figure 2. Evaluation unit (EU)-level prevalence of trichiasis unknown to the health system in ≥15-year-olds, adjusted for gender and
age (see text), Global Trachoma Mapping Project, Pakistan, October–December 2015.
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might be an option, though compliance with the pro-
longed course of treatment required could be anticipated
to be low44, particularly amongst the large numbers of
asymptomatic and minimally symptomatic individuals
who would be offered it in a mass treatment campaign.
Intensive implementation of the F and E components of
the SAFE strategy45,46 could be another solution. We note
that the prevalence of household-level access to water
and sanitation varied markedly between EUs (Table 3),
though several of the EUs with TF prevalence ≥5%
already had levels of access to these services that associate
with lower risk of (and even, for sanitation coverage
≥80%, “herd protection” against) active trachoma.47,48
We also note that the evidence base for the F and
E interventions is weak.49–51
Not all trichiasis is caused by trachoma.52 Pakistan was
one of the first GTMP deployments in which we were
able to explore the effect of separating out trichiasis seen
in association with TS from trichiasis noted in its absence.
Guided by the Second Global Scientific Meeting on
Trachomatous Trichiasis,33 half-way through this series
of surveys, we asked field teams to start recording
whether or not scarring was clearly visible in the con-
junctivae of eyes with trichiasis; where they were unable
to evert the eyelid to check, TS was assumed to be pre-
sent. In this low-prevalence setting, this would have made
a difference to the categorization of EUs as requiring or
not requiring public health-level “S” interventions in only
one instance. Further work to better understand the
epidemiology, phenotypes and vision-threatening poten-
tial of trichiasis with and without visible scar is needed.53
Building on results from the GTMP in Pakistan and
elsewhere,54 momentum towards global elimination of
trachoma is progressively building.55–57 In April 2018, in
London, Commonwealth Heads of Government pledged
their commitment to the global target58 and the United
Kingdom re-affirmed financial support.59 It is recom-
mended that stakeholders in Pakistan take advantage of
Table 3. Household-level access to water and sanitation, by evaluation unit, Global Trachoma Mapping Project, Pakistan,
October–December 2015.
Evaluation unit (* asterisked evaluation units are those in which
the estimated TF prevalence was ≥5%)
Households,
n
Improved washing
water, n (%)
Washing water
<1km, n (%)
Improved
latrine, n (%)
Chattar Sub-Tehsil, Dera Murad Jamali Tehsil 780 290 (37) 740 (95) 214 (27)
Nushki Tehsil 780 602 (77) 571 (73) 445 (57)
Banda Daud Shah Tehsil, Karak Tehsil* 1119 979 (87) 1023 (91) 895 (80)
Takhat Nasrati Tehsil* 633 559 (88) 560 (88) 430 (68)
Bala Kot Tehsil 781 770 (99) 770 (99) 759 (97)
FR Kala Dhaka* 781 563 (72) 672 (86) 406 (52)
Mansehra Tehsil 1 792 718 (91) 790 (100) 741 (94)
Mansehra Tehsil 2 782 767 (98) 743 (95) 736 (94)
Oghi Tehsil* 785 742 (95) 739 (94) 707 (90)
Mardan Tehsil 1* 812 811 (100) 812 (100) 693 (85)
Mardan Tehsil 2* 1024 937 (92) 1018 (99) 801 (78)
Mardan Tehsil 3 511 504 (99) 511 (100) 430 (84)
Takht Bhai Tehsil 812 811 (100) 811 (100) 620 (76)
Gujranwala Tehsil 1 890 889 (100) 890 (100) 887 (100)
Gujranwala Tehsil 2 654 654 (100) 654 (100) 654 (100)
Kamoke Tehsil 758 758 (100) 758 (100) 749 (99)
Nowshera Tehsil 796 796 (100) 796 (100) 794 (100)
Wazirabad Tehsil 1 850 847 (100) 844 (99) 828 (97)
Wazirabad Tehsil 2 687 687 (100) 687 (100) 668 (97)
Choubara Tehsil 1126 1122 (100) 1126 (100) 583 (52)
Karor Tehsil 761 761 (100) 761 (100) 728 (96)
Leiah Tehsil 1 814 814 (100) 814 (100) 771 (95)
Leiah Tehsil 2 795 795 (100) 795 (100) 641 (81)
Dunyapur Tehsil 757 747 (99) 752 (99) 653 (86)
Kahror Tehsil 712 712 (100) 712 (100) 415 (58)
Lodhran Tehsil 1 758 758 (100) 757 (100) 426 (56)
Lodhran Tehsil 2 819 758 (93) 780 (95) 658 (80)
Chichawatni Tehsil 1 750 750 (100) 750 (100) 663 (88)
Chichawatni Tehsil 2 761 760 (100) 760 (100) 641 (84)
Sahiwal Tehsil 1 814 811 (100) 784 (96) 695 (85)
Sahiwal Tehsil 2 799 795 (99) 701 (88) 620 (78)
Sahiwal Tehsil 3 994 993 (100) 983 (99) 927 (93)
Dahrki Taluka 780 777 (100) 780 (100) 779 (100)
Ghotki Taluka, Khangarh Taluka 809 809 (100) 809 (100) 492 (61)
Mirpur Mathelo Taluka, Ubauro Taluka 787 787 (100) 712 (90) 133 (17)
Sehwan Taluka 784 473 (60) 444 (57) 359 (46)
Dhirkot, Bagh, Hari Ghal 752 744 (99) 741 (99) 745 (99)
Kotli Sub-Tehsil 1 760 707 (93) 740 (97) 746 (98)
Kotli Sub-Tehsil 2 795 795 (100) 765 (96) 772 (97)
Kotli Sub-Tehsil 3 731 313 (43) 649 (89) 657 (90)
Ghizer 780 656 (84) 755 (97) 694 (89)
Ghanche 767 594 (77) 712 (93) 48 (6)
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these developments, rapidly complete planning using the
data presented here, and implement a national programme
that can bring about trachoma elimination nationwide.
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